Streetbeat News

IPSEY

Ipsen

https://www.ipsen.com/

CEO

David Loew

Industry

Medicinal and Botanical Manufacturing

Open

29.00

Mkt cap

9.5B

Volume

4.5K

High

29.00

P/E Ratio

13.71

52-wk high

34.06

Low

28.65

Div yield

0.01

52-wk low

27.00

Eton Pharmaceuticals has entered an agreement to acquire Increlex, a biologic product for treating severe primary insulin-like growth factor 1 deficiency, from Ipsen. The terms of the deal were not disclosed. Increlex is approved in 40 territories, including the U.S. and EU, and is the only FDA and EMA approved treatment for SPIGFD.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 10:35 am

Ipsen and Day One Biopharmaceuticals have announced an exclusive ex-U.S. licensing agreement to commercialize tovorafenib for pediatric low grade glioma. Ipsen will handle regulatory and commercial activities outside the U.S., while Day One will receive an upfront payment of $111 million and up to $350 million in milestone payments.

Portfolio Pulse from charles@benzinga.com

July 25, 2024 | 10:10 am

Ipsen has secured ex-U.S. rights to tovorafenib, a drug for pediatric brain cancer, from Day One. Day One will receive $111 million upfront and up to $350 million in milestone payments, plus royalties. The drug is FDA-approved for relapsed or refractory pediatric low-grade glioma and is undergoing a Phase III trial for newly diagnosed cases.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:54 am

The FDA has granted accelerated approval for Ipsen and Genfit's new liver disease treatment, Iqirvo, to treat primary biliary cholangitis (PBC). The drug, developed by Genfit and commercialized by Ipsen, is now available for prescription in the U.S. and is expected to generate substantial milestone payments for Genfit.

Portfolio Pulse from Shivani Kumaresan

June 11, 2024 | 1:18 pm

GENFIT's Iqirvo, the first-ever drug developed in-house by the company, has received FDA approval. GENFIT is set to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale in the U.S., along with tiered double-digit royalties up to 20%.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 9:26 pm

Ipsen announced that Iqirvo has secured FDA accelerated approval as the first-in-class PPAR treatment for primary biliary cholangitis. Iqirvo, an oral, once-daily PPAR agonist, was in-licensed from GENFIT in 2021.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 8:59 pm

Ipsen and Skyhawk Therapeutics have announced a partnership to develop RNA-based treatments for rare neurological conditions. This collaboration aims to leverage Skyhawk's expertise in RNA splicing to address unmet medical needs in neurology.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 6:41 am

Ipsen and Sutro Biopharma have entered into an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate targeting solid tumors. Ipsen will have global rights for the development and commercialization of STRO-003, which is in the final stages of pre-clinical development and targets ROR1. STRO-003 has demonstrated strong efficacy and a potential for a differentiated safety profile in preclinical studies.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 5:49 am

Merrimack Pharmaceuticals received a $225 million milestone payment from Ipsen for FDA approval of ONIVYDE for metastatic adenocarcinoma of the pancreas. Merrimack's Board sees no further payments from Ipsen or Elevation Oncology agreements likely and plans a dissolution meeting for May 10, 2024, to discuss a liquidating dividend.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:34 pm

Merrimack Pharmaceuticals may receive up to $450M in additional payments from Ipsen following the sale of its oncology assets, including ONIVYDE, contingent upon the approval of new indications for ONIVYDE in the U.S.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 6:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.